1. Introduction {#sec1}
===============

Quinones are among the most frequently used chemotherapy drugs in the treatment of cancer \[[@B1]\]. Their antitumor action has been attributed to DNA crosslinking, leading to inhibition of DNA synthesis and monoadduct formation and induction of apoptosis and cell death \[[@B2]--[@B5]\]. This DNA damage, as well as drug-associated adverse events such as cardiovascular and skin toxicity, may be related to the formation of reactive oxygen species (ROS) \[[@B6], [@B7]\].

Mitomycin C (MMC) is a quinone-containing antibiotic originally isolated from *Streptomyces caespitosus* in 1958 \[[@B8]\]. MMC has been used to treat a wide variety of solid tumors. Although current use of MMC is limited, this agent continues to be a key element in several clinical trials due to its intrinsic efficacy against many solid tumors and preferential activity in hypoxic tumoral cells \[[@B9]\]. MMC has a synergistic effect with radiotherapy via its radiosensitizing effects, targeting hypoxic cells in radiation resistant tumors \[[@B10], [@B11]\]. To achieve its alkylating activity, MMC requires a bioreductive transformation to form active species that crosslink DNA \[[@B12]--[@B14]\]. Depending on the biotransformation pathway, metabolism of MMC may generate ROS \[[@B15]\]. When ROS interact with cells and exceed endogenous antioxidant systems, there is indiscriminate damage to biological macromolecules such as nucleic acids, proteins, and lipids \[[@B16]\].

Melatonin, N-acetyl-5-methoxytryptamine, is the chief product of the pineal gland in all vertebrates. Retinal light exposure reduces the amount of serotonin metabolized to melatonin via neural pathways connecting the retina to the pineal gland. Thus, pineal production of melatonin increases at night, and the amount of melatonin secreted into the plasma is related to the length of exposure to darkness \[[@B17]\]. Melatonin is involved in the modulation of a variety of endocrine, neural, and immune functions \[[@B17], [@B18]\]. Recently, it has been reported to have significant antioxidant activity \[[@B19]--[@B22]\]. Its protection against oxidative damage is enhanced by its amphiphilic nature, allowing the melatonin molecule to readily access all cell compartments, including the nucleus \[[@B23]\]. Intensive research over the last two decades has shown the beneficial protective effects of melatonin in a multitude of pathological processes. Among them, its anticarcinogenic property has attracted considerable attention \[[@B23], [@B24]\]. There is compelling evidence that melatonin may reduce the growth of established tumors \[[@B25]\].

Since cellular harm produced by MMC is thought to be at least partially due to a free radical mechanism, and MMC generates micronuclei-induced genotoxic damage in animal models \[[@B26], [@B27]\], the aim of this work was to assess the genotoxic effect of MMC. These effects were measured as the number of micronucleated polychromatic erythrocytes (MN-PCE) from the peripheral blood and the ability of MMC to induce lipid peroxidation in cerebral and hepatic homogenates. We also assessed the potential protective action of melatonin against both micronuclei formation and lipid peroxidation processes due to MMC.

2. Material and Methods {#sec2}
=======================

2.1. Chemicals {#sec2.1}
--------------

Analytical grade agents were obtained from reputable commercial sources. MMC and melatonin were purchased from Sigma-Aldrich (Madrid, Spain). The Bioxytech LPO-586 kit for lipid peroxidation was obtained from Cayman Chemical (Ann Arbor, MI, USA).

2.2. Animal Care and Randomization {#sec2.2}
----------------------------------

Thirty-six Sprague-Dawley rats weighing 95--100 g were purchased from Harlan Iberica (Barcelona, Spain) and received standard food and water *ad libitum*. Animal handling and procedures were in strict accordance with the recommendations of the European Economic Community Committee (2007/526/CE) for the care and use of laboratory animals. The experimental protocol was approved by Zaragoza\'s University Ethical Committee for Animal Research (reference PI24/09).

After acclimation for two weeks with a 12-hour light/dark cycle (lights on at 0700 and off at 1900), the rats were divided to four groups of nine animals in each: control, melatonin, MMC, and MMC + melatonin. MMC was dissolved in saline and injected intraperitoneally in a single dose of 2 mg/kg. Melatonin was dissolved in ethanol and thereafter diluted in saline (final concentration of ethanol: 1%) and administered intraperitoneally in a dose of 10 mg/kg. Melatonin treatment started 24 hours prior to MMC administration and was given every 8 hours. Control and MMC groups received the dose intraperitoneally and with an equal volume of ethanol/saline solution.

2.3. Tissue Preparation {#sec2.3}
-----------------------

A 5 *μ*L peripheral blood sample was collected from the tail vein of each rat at 0, 24, 48, 72, and 96 hours after MMC treatment and mounted on two glass slides. Afterwards, the extensions were fixed with methanol for 10 minutes. Following final blood extractions, at 96 hours, the animals were decapitated and the brain and liver were quickly removed, washed in cold saline solution (4°C), and frozen below −30°C until MDA + 4-HDA assay was performed.

2.4. Peripheral Blood Micronucleus Test {#sec2.4}
---------------------------------------

Peripheral blood slides were stained with an acridine orange (AO) fluorescent staining procedure according to Hayashi et al. \[[@B28]\]. A volume of 0.24 mmol AO in phosphate buffer (PBS) was used as the working solution. The methanol-fixed slides were stained for 3 minutes at room temperature. Each slide was rinsed twice for three minutes. The excess of buffer was removed with paper. The slides were mounted with the same buffer, covered with a 24 × 60 mm cover slip, and sealed with paraffin. Using coded slides, the analysis of MN-PCE in each slide was done within 1--2 days by two independent researchers, each analyzing one thousand cells. Utilizing a fluorescent microscope (Zeiss III-RS), the number of MN-PCE per 1000 polychromatic erythrocytes (PCE) was counted and, the ratio of PCE to normochromatic erythrocytes (PCE/NCE) was calculated (from 300 erythrocytes). Subsequently, the code was broken and the counts from each evaluator were averaged. With the AO fluorescent staining procedure, PCE containing RNA can be identified by red fluorescence and micronuclei by yellow-green fluorescence. The number of the MN-PCE was expressed per 1000 PCE.

2.5. Measurement of MDA and 4-HDA {#sec2.5}
---------------------------------

MDA + 4-HDA levels were used as an index of oxidative breakdown of lipids in brain and liver tissues \[[@B29]\]. Briefly, samples were homogenized (1 : 5) (weight/volume) in 20 mmol tris(hydroxymethyl) aminomethane buffer (pH 7.4). MDA + 4-HDA were determined using the Bioxytech kit. In the assay, MDA plus 4-HDA reacts with N-methyl-2-phenylindole, yielding a stable chromophore with a peak of maximum absorbance at 586 nm. Results were expressed as nmol of MDA + 4-HDA per mg of protein. Protein concentrations in the tissue homogenates were assessed by the Bradford method using bovine serum albumin as a standard \[[@B30]\].

2.6. Statistical Analysis {#sec2.6}
-------------------------

Results were expressed as means ± standard errors. Student\'s unpaired data *t*-test and ANOVA were used for comparison of the means. A *P* value \< .05 was considered statistically significant.

3. Results {#sec3}
==========

The results of the micronucleus assay obtained in peripheral blood are illustrated in [Figure 1](#fig1){ref-type="fig"}. The number of MN-PCE at 24, 48, 72, and 96 hours increased significantly in the groups exposed to MMC compared to other groups. No differences were observed in the PCE/NCE ratio ([Table 1](#tab1){ref-type="table"}). The maximal response was observed 48 hours after MMC administration. When compared to MMC alone, melatonin significantly reduced the number of MMC-induced MN-PCE in peripheral blood at 24 hours (6.6 ± 0.92 versus 4 ± 0.67; *P* = .038), 48 hours (14.3 ± 4.77 versus 5.9 ± 0.54; *P* = .020), 72 hours (7.1 ± 1.35 versus 3 ± 0.41; *P* = .04), and 96 hours (3.5 ± 0.65 versus 1 ± 0.24; *P* = .03) while no differences were appreciated between controls (1.8 ± 0.63 versus 1.5 ± 0.43; *P* = .6).

No statistically significant differences of MDA + 4-HDA were found in brain or liver when the averages of each group were compared ([Figure 2](#fig2){ref-type="fig"}). These results indicate the absence of lipid peroxidation due to MMC in these organs under our experimental conditions.

4. Discussion {#sec4}
=============

Our results show that in vivo exposure to MMC induces genotoxicity as indicated by increases in the number of MN-PCE at 24, 48, 72, and 96 hours posttreatment. This is in accordance with previous studies demonstrating MMC-induced micronuclei \[[@B26], [@B31], [@B32]\]. Several in vitro and in vivo studies have shown that different MMC metabolic pathways result in ROS generation \[[@B33]--[@B35]\], and that some MMC metabolites may form cross-links to adjacent guanines in DNA \[[@B36]--[@B39]\]. Quinones, including MMC, streptonigrin, and adriamycin, produce ROS as result of one- or two-electron reduction metabolism \[[@B40]--[@B42]\]: firstly, they or their one-electron reduction product, semiquinones (SQ•^−^), may react with glutathione and protein-SH groups through a nonenzymatic and/or glutathione transferase reaction; secondly, SQ•^−^ may generate superoxide anion radicals depending on the equilibrium potential and the pH \[[@B43], [@B44]\]; thirdly, SQ•^−^ and superoxide anion radicals can reduce transition-metal ions, such as iron and copper, and promote the hydroxyl radical generation via the Fenton reaction \[[@B33], [@B45]\].

On the other hand, our results show that, after 96 hours of MMC treatment, this quinone does not induce lipid peroxidation in homogenates of brain and liver, as indicated by its inability to modify significantly MDA + 4-HDA concentrations. However, free radicals involve the micronuclei formation \[[@B46]\] and we have demonstrated that the antioxidant indoleamine melatonin had a protective effect against MMC genotoxicity in rat red blood cell precursors in vivo, suggesting that MMC-induced PCE-MN elevation may be mediated by free radical generation. Possible explanations for the lack of lipid peroxidation induced by MMC could be that the ROS generated as a consequence of MMC metabolism is insufficiently powerful to generate or propagate lipid peroxidation or that, after 96 hours, MDA + 4-HDA concentrations were reduced by renal clearance.

Recent interest has focused on the use of molecules that may partly reduce the side effects of MMC. Several free radical scavenger agents, such as amifostine and nitroxide, prevent the cytotoxic damage mediated by MMC in different organs \[[@B47]--[@B49]\]. In fact, the United States Food and Drug Administration (FDA) recently approved amifostine for use as a cytoprotectant in combination with cyclophosphamide and cisplatin for the treatment of advanced ovarian cancer and nonsmall cell lung cancer \[[@B50]\]. Lipoic acid, another antioxidant, has also demonstrated an in vivo dose-dependent protective effect against cyclophosphamide-induced clastogenicity in the peripheral blood and bone marrow of rats \[[@B51]\]. Herein, we have extended the evidence of melatonin as a cell protector, since cotreatment of MMC and melatonin significantly reduced the number of MN-PCE. This is in accordance with the results of previous studies showing a significant reduction in micronuclei induction by different genotoxic molecules in peripheral blood and bone marrow samples \[[@B52], [@B53]\]. Moreover, melatonin is also capable of preventing DNA damage induced by not only mutagens but also different alkylating agents such as 7,12-dimethybenz(*α*)anthracene, cyclophosphamide, and benzo(*α*)pyrene \[[@B54]\].

Melatonin protection against DNA damage and oncogenesis is thought to be due in part to its antioxidant properties. Melatonin, an indoleamine, directly scavenges hydroxyl radicals, singlet oxygen, and peroxynitrites \[[@B19], [@B55]--[@B57]\], increases the concentration of endogenous glutathione, and stimulates the antioxidative enzymes superoxide dismutase and glutathione peroxidase \[[@B58]\]. Moreover, melatonin has been shown to prevent iron-induced lipid peroxidation \[[@B59]\]. Thus melatonin may also prevent carcinogenesis \[[@B60]\].

Additionally, once oncogenesis has occurred; melatonin seems to control cancer growth by means other than its antioxidant activity. Melatonin might inhibit the uptake and metabolism of fatty acid signaling molecules that promote the production of tumoral growth factors \[[@B61]\], reduce telomerase activity by shortening telomer length \[[@B62]\], and modulate expression of tumor suppressor genes such as TP53 \[[@B63]\]. More recent studies report that melatonin significantly suppresses endothelin-1 converting enzyme activity \[[@B64]\]. Endothelin-1 is a potent vasoconstrictor peptide that is involved in angiogenesis and cancer growth. This peptide is usually elevated in the plasma of patient with various solid tumors and acts to protect cancer cells from apoptosis and promote endothelial and smooth muscle proliferation \[[@B65]\]. Finally, the antiestrogenic activity of melatonin also seems to play a role in its ability to decrease proliferation in some hormone-responsive tumors. Physiological and pharmacological concentrations of melatonin exhibited a growth inhibitory effect on MCF-7 human breast cancer cell lines \[[@B66], [@B67]\]. In fact, this effect was particularly manifested in cancer cell lines possessing the estrogen receptor *α* (ER*α*); this effect seems to be mediated by both membrane (MT1) and nuclear (RZR*α*) melatonin receptors \[[@B68]\].

5. Conclusion {#sec5}
=============

In conclusion, the data reported herein provide evidence that melatonin reduces genotoxicity due to MMC, presumably due to its antioxidant effects. Based on our observations and previous results showing that oxidative stress participates in carcinogenesis and the role of melatonin as an anticarcinogenic agent with broad bioavailability and lack of side effects \[[@B23]\], it seems reasonable to propose that cotreatment with melatonin may be beneficial when used in combination with MMC for the treatment of some cancers.
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![Micronucleated polychromatic erythrocytes (MN-PCE) per 1000 polychromatic erythrocytes (PCE) in peripheral blood at 0, 24, 48, 72, and 96 hours in four rat groups (*n* = 9): control, mitomycin (MMC), melatonin, and MMC + melatonin. Data are expressed as means ± standard error. *P* \< 0.05 versus control (\*) or versus MMC (\#).](JBB2009-791432.001){#fig1}

![Malondialdehyde (MDA) plus 4-hydroxyalkenals (4-HDA) concentrations in brain (a) and liver (b) homogenates from rats in the presence or absence of treatment with mitomycin C (MMC) or melatonin. Values are mean ± standard error.](JBB2009-791432.002){#fig2}

###### 

The ratio of polychromatic erythrocytes/normochromatic erythrocytes (PCE/NCE) in rat peripheral blood after 0, 24, 48, 72, and 96 hours in the four treatment groups

  Treatment   PCE/NCE ratio (mean ± standard error)                                             
  ----------- --------------------------------------- ------------- ------------- ------------- -------------
  Control     2.34 ± 0.05                             2.13 ± 0.06   2.34 ± 0.02   2.28 ± 0.08   2.22 ± 0.03
  aMT         2.35 ± 0.07                             2.35 ± 0.07   2.19 ± 0.07   2.23 ± 0.03   2.30 ± 0.03
  MMC         2.22 ± 0.06                             2.13 ± 0.03   2.11 ± 0.10   2.20 ± 0.06   2.10 ± 0.09
  MMC + aMT   1.95 ± 0.04                             2.09 ± 0.07   2.05 ± 0.02   2.10 ± 0.07   2.16 ± 0.05

MMC: mitomycin C; aMT: melatonin

[^1]: Recommended by Gary S. Stein
